Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Chronic viral hepatitis--benefits of current therapies.

Literature DB >> 8618588

Chronic viral hepatitis--benefits of current therapies.

J H Hoofnagle, D Lau.

Abstract

Entities: Disease

Mesh：

Substances：

Year: 1996 PMID： 8618588 DOI： 10.1056/NEJM199605303342210

Source DB: PubMed Journal: N Engl J Med ISSN： 0028-4793 Impact factor: 91.245

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

Review 1. [Therapy of hepatitis C].

Authors: D M Alscher; J C Bode
Journal: Med Klin (Munich) Date: 1997-03-15

2. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

Authors: K Sandres; M Dubois; C Pasquier; J L Payen; L Alric; M Duffaut; J P Vinel; J P Pascal; J Puel; J Izopet
Journal: J Virol Date: 2000-01 Impact factor: 5.103

3. A pharmacokinetic model for alpha interferon administered subcutaneously.

Authors: E Chatelut; L Rostaing; N Grégoire; J L Payen; A Pujol; J Izopet; G Houin; P Canal
Journal: Br J Clin Pharmacol Date: 1999-04 Impact factor: 4.335

4. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial.

Authors: M Francesca Jaboli; Carlo Fabbri; Stefania Liva; Francesco Azzaroli; Giovanni Nigro; Silvia Giovanelli; Francesco Ferrara; Anna Miracolo; Sabrina Marchetto; Marco Montagnani; Antonio Colecchia; Davide Festi; Letizia Bacchi Reggiani; Enrico Roda; Giuseppe Mazzella
Journal: World J Gastroenterol Date: 2003-07 Impact factor: 5.742

Chronic viral hepatitis--benefits of current therapies.

Review 1. [Therapy of hepatitis C].

2. Genetic heterogeneity of hypervariable region 1 of the hepatitis C virus (HCV) genome and sensitivity of HCV to alpha interferon therapy.

3. A pharmacokinetic model for alpha interferon administered subcutaneously.

4. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial.

5. Viral hepatitis and the surgeon.

6. Bile acids promote the expression of hepatitis C virus in replicon-harboring cells.

7. Saturable human neopterin response to interferon-α assessed by a pharmacokinetic-pharmacodynamic model.